Topical steroid versus placebo for the prevention of radiation dermatitis in head and neck cancer patients receiving chemoradiotherapy: The study protocol of J-SUPPORT 1602 (TOPICS study), a randomized double-blinded phase 3 trial

Sadamoto Zenda, Takuhiro Yamaguchi, Tomoya Yokota, Tempei Miyaji, Tomoe Mashiko, Mari Tanaka, Masahito Yonemura, Misaki Takeno, Tomoka Okano, Toshikatsu Kawasaki, Yuko Nakamori, Shinobu Ishii, Sanae Shimada, Miyuki Kanamaru, Yosuke Uchitomi

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)

Abstract

Background: To date, the clinical benefit of topical steroid use has only been demonstrated for radiation dermatitis induced by 50-60 Gy irradiation in breast cancer. However, these agents are also often used clinically for the control of radiation dermatitis induced by high-dose (>60Gy) irradiation with chemotherapy in head and neck cancer. Despite this, the prophylactic efficacy of topical steroids for radiation dermatitis induced by high-dose irradiation is still unclear. The aim of this study is to clarify the benefit of topical steroids in basic nursing care for radiation dermatitis induced by chemoradiotherapy in patients with head and neck cancer. Methods: The study is being conducted as a multicenter 2-arm randomized double-blinded placebo-controlled Phase 3 trial in Japan. The study was started in May 2017, with participant enrollment between May 2017 and April 2019. Patients scheduled to receive definitive or postoperative chemoradiotherapy for head and neck cancer are eligible for enrollment. All patients will receive chemoradiotherapy, consisting of single agent CDDP and 70-Gy irradiation. Bilateral neck irradiation is mandatory. Supportive care for radiation dermatitis will consist of basic nursing care with topical steroid or placebo. When radiation dermatitis grade 1 is seen or total radiation dose reaches 30 Gy, minimally required intervention will be started as a first step. If radiation dermatitis worsens to grade 2, the irradiated area will be covered with a moderately absorbent surgical pad and steroid or placebo topical cream. The primary endpoint is a comparison of the proportion of patients with ≥ grade 2 radiation dermatitis by NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Ethical approval has been obtained from all participating sites. The results of this study will be submitted for publication in international peer-reviewed journals and the key findings will be presented at international scientific conferences. Discussion: Evidence supporting the benefit of adding topical steroids in general nursing care for radiation dermatitis induced by high-dose irradiation with chemotherapy is insufficient. This trial aims to clarify the clinical benefit of topical steroid for radiation dermatitis induced by high-dose irradiation with chemotherapy. The trial is ongoing and is currently recruiting.

Original languageEnglish
Article number873
JournalBMC Cancer
Volume18
Issue number1
DOIs
Publication statusPublished - 2018 Sep 6
Externally publishedYes

Keywords

  • Chemoradiotherapy
  • Head and neck
  • Nursing
  • Radiation dermatitis
  • Topical steroid

ASJC Scopus subject areas

  • Genetics
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Topical steroid versus placebo for the prevention of radiation dermatitis in head and neck cancer patients receiving chemoradiotherapy: The study protocol of J-SUPPORT 1602 (TOPICS study), a randomized double-blinded phase 3 trial'. Together they form a unique fingerprint.

Cite this